CASI Pharmaceuticals, Inc. (CASI) Reaches New 12-Month High at $1.84
CASI Pharmaceuticals, Inc. (NASDAQ:CASI) hit a new 52-week high on Monday . The stock traded as high as $1.84 and last traded at $1.84, with a volume of 463,140 shares changing hands. The stock had previously closed at $1.50.
CASI has been the subject of several analyst reports. Maxim Group reissued a “buy” rating and set a $4.00 price target on shares of CASI Pharmaceuticals in a research report on Friday, September 8th. ValuEngine raised shares of CASI Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Friday. Finally, HC Wainwright reissued a “buy” rating and set a $2.00 price target on shares of CASI Pharmaceuticals in a research report on Friday, September 8th.
The company’s market capitalization is $107.75 million. The company has a 50 day moving average of $1.02 and a 200-day moving average of $1.12.
CASI Pharmaceuticals (NASDAQ:CASI) last posted its quarterly earnings data on Monday, August 14th. The biotechnology company reported ($0.04) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.03) by ($0.01). Equities analysts predict that CASI Pharmaceuticals, Inc. will post ($0.15) earnings per share for the current year.
TRADEMARK VIOLATION NOTICE: This news story was originally published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this news story on another domain, it was stolen and republished in violation of US & international trademark and copyright laws. The correct version of this news story can be accessed at https://www.thecerbatgem.com/2017/09/18/casi-pharmaceuticals-inc-casi-reaches-new-12-month-high-at-1-84.html.
CASI Pharmaceuticals Company Profile
CASI Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the acquisition, development and commercialization of therapeutics for cancer and other medical needs. It operates through the development of targeted therapeutics for the treatment of cancer segment. Its product pipeline includes internal development of its lead drug candidate, ENMD-2076; MARQIBO, ZEVALIN and EVOMELA, and early-stage candidates in preclinical development.
Receive News & Stock Ratings for CASI Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CASI Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.